Covered recipient · General Payments record
CHRISTOPHER A SMITH
Allopathic & Osteopathic Physicians Allergy & Immunology Allergy
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$104,459.28
252 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $86,598.00 | 29 |
| Travel and Lodging | $7,492.07 | 42 |
| Food and Beverage | $5,555.07 | 178 |
| Consulting Fee | $4,750.00 | 1 |
| Education | $64.14 | 2 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $42,163.38 | 77 |
| GENZYME CORPORATION | $24,118.44 | 25 |
| GlaxoSmithKline, LLC. | $17,031.78 | 35 |
| Regeneron Healthcare Solutions, Inc. | $9,675.79 | 20 |
| Genentech, Inc. | $6,686.24 | 5 |
| Amgen Inc. | $3,116.29 | 12 |
| Grifols USA, LLC | $315.36 | 8 |
| PFIZER INC. | $304.30 | 17 |
| Takeda Pharmaceuticals U.S.A., Inc. | $224.64 | 10 |
| OptiNose US, Inc. | $176.08 | 9 |
| Teva Pharmaceuticals USA, Inc. | $116.36 | 7 |
| Novartis Pharmaceuticals Corporation | $89.35 | 4 |
| ABBVIE INC. | $89.05 | 4 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $67.67 | 3 |
| Genentech USA, Inc. | $66.98 | 5 |
| ADMA BioManufacturing LLC | $34.66 | 2 |
| Octapharma USA, Inc. | $28.99 | 1 |
| CSL Behring | $27.41 | 1 |
| Horizon Therapeutics plc | $23.00 | 1 |
| BioCryst US Sales Co., LLC | $21.61 | 1 |
| kaleo, Inc. | $18.13 | 1 |
| Incyte Corporation | $17.64 | 1 |
| ALK-Abello, Inc | $16.91 | 1 |
| Bardy Diagnostics, Inc. | $15.00 | 1 |
| Bio Products Laboratory USA, Inc. | $14.22 | 1 |
Page 3 of 6; records 101–150 of 252 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
CHRISTOPHER A SMITH
NPI 1679675995 · CMS profile ID 302642
Allopathic & Osteopathic Physicians / Allergy & Immunology / Allergy
HORSEHEADS, NY
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 6; records 101–150 of 252 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1679675995?year=2022&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- CHRISTOPHER A SMITH, NPI 1679675995, CMS profile ID 302642. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 252 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679675995?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). CHRISTOPHER A SMITH, NPI 1679675995, CMS profile ID 302642. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 252 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679675995?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- CHRISTOPHER A SMITH, NPI 1679675995, CMS profile ID 302642, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 252 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1679675995?year=2022&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
252 matching records · $104,459.28 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 252.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| CSL Behring | $27.41 | 08/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940895217 | CMS |
| AstraZeneca Pharmaceuticals LP | $196.08 | 08/11/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920242103 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.00 | 08/11/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920245853 | CMS |
| AstraZeneca Pharmaceuticals LP | $113.50 | 08/11/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920261691 | CMS |
| AstraZeneca Pharmaceuticals LP | $120.53 | 08/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920263717 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.99 | 08/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920249325 | CMS |
| GlaxoSmithKline, LLC. | $1.17 | 08/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 945096355 | CMS |
| Amgen Inc. | $12.33 | 08/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939438255 | CMS |
| GlaxoSmithKline, LLC. | $8.98 | 08/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 945096303 | CMS |
| Horizon Therapeutics plc | $23.00 | 08/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937698827 | CMS |
| PFIZER INC. | $18.30 | 08/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949238357 | CMS |
| PFIZER INC. | $2.35 | 08/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949256623 | CMS |
| ABBVIE INC. | $18.86 | 08/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891625541 | CMS |
| Teva Pharmaceuticals USA, Inc. | $9.73 | 07/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954612446 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.35 | 07/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920255015 | CMS |
| Regeneron Healthcare Solutions, Inc. | $467.00 | 07/26/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927411623 | CMS |
| OptiNose US, Inc. | $18.29 | 07/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 928142689 | CMS |
| GENZYME CORPORATION | $28.61 | 07/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938817713 | CMS |
| Amgen Inc. | $16.18 | 07/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939438249 | CMS |
| Regeneron Healthcare Solutions, Inc. | $4,203.00 | 07/14/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927411613 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $20.36 | 07/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955832533 | CMS |
| ABBVIE INC. | $22.71 | 07/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891625539 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.41 | 07/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920229393 | CMS |
| Regeneron Healthcare Solutions, Inc. | $17.84 | 07/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927411605 | CMS |
| Amgen Inc. | $24.99 | 07/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939438241 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,700.00 | 06/30/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920255589 | CMS |
| GlaxoSmithKline, LLC. | $14.73 | 06/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 945096295 | CMS |
| AstraZeneca Pharmaceuticals LP | $146.25 | 06/28/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920227523 | CMS |
| AstraZeneca Pharmaceuticals LP | $113.34 | 06/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920234409 | CMS |
| AstraZeneca Pharmaceuticals LP | $226.44 | 06/28/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920248831 | CMS |
| Bio Products Laboratory USA, Inc. | $14.22 | 06/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937420085 | CMS |
| OptiNose US, Inc. | $19.60 | 06/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 928142675 | CMS |
| GENZYME CORPORATION | $45.15 | 06/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938817715 | CMS |
| GENZYME CORPORATION | $4,203.00 | 06/22/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938817717 | CMS |
| GENZYME CORPORATION | $143.36 | 06/22/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938817719 | CMS |
| PFIZER INC. | $20.86 | 06/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949178259 | CMS |
| PFIZER INC. | $24.01 | 06/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949618761 | CMS |
| GlaxoSmithKline, LLC. | $10.56 | 06/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 945096323 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.25 | 06/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920233819 | CMS |
| GENZYME CORPORATION | $104.32 | 06/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938817721 | CMS |
| GENZYME CORPORATION | $3,269.00 | 06/15/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938817723 | CMS |
| GENZYME CORPORATION | $4.50 | 06/15/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938817725 | CMS |
| Teva Pharmaceuticals USA, Inc. | $10.71 | 06/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954612581 | CMS |
| GlaxoSmithKline, LLC. | $19.97 | 06/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 945096325 | CMS |
| Grifols USA, LLC | $23.60 | 06/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918681275 | CMS |
| Grifols USA, LLC | $17.22 | 06/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918691007 | CMS |
| Genentech, Inc. | $190.54 | 06/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950662925 | CMS |
| Genentech, Inc. | $280.00 | 06/10/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950662831 | CMS |
| Genentech, Inc. | $1,275.16 | 06/10/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950662895 | CMS |
| Genentech, Inc. | $190.54 | 06/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950662959 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,650,793.03 | 108 |
| PY2024 | Principal investigator | $3,249,344.65 | 151 |
| PY2023 | Principal investigator | $5,560,565.13 | 232 |
| PY2022 | Principal investigator | $4,620,075.95 | 221 |
| PY2021 | Principal investigator | $764,750.18 | 79 |
| PY2020 | Principal investigator | $248,688.67 | 85 |
| PY2019 | Principal investigator | $235,242.43 | 52 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
108 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $79.62 | 12/31/2025 | Non-covered Recipient Entity Certified Research Associates | A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age | No dispute reported | 06/30/2026 | 1232933230 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $79.62 | 12/31/2025 | Non-covered Recipient Entity Corning Center For Clinical Research | A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age | No dispute reported | 06/30/2026 | 1232933402 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $0.38 | 12/31/2025 | Non-covered Recipient Entity Certified Research Associates | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine wi | No dispute reported | 06/30/2026 | 1232934292 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $0.32 | 12/31/2025 | Non-covered Recipient Entity Corning Center for Clinical Research | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine wi | No dispute reported | 06/30/2026 | 1232934516 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $47,408.00 | 12/31/2025 | Non-covered Recipient Entity Certified Research Associates | A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent | No dispute reported | 06/30/2026 | 1232937520 |
| Principal investigator 1 | PFIZER INC. | $4,758.75 | 12/31/2025 | Non-covered Recipient Entity Christopher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228723568 |
| Principal investigator 1 | PFIZER INC. | $47,801.59 | 12/31/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1228735745 |
| Principal investigator 1 | PFIZER INC. | $3,807.00 | 12/31/2025 | Non-covered Recipient Entity Christpher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228745158 |
| Principal investigator 1 | PFIZER INC. | $35,874.31 | 12/31/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1228746141 |
| Principal investigator 1 | PFIZER INC. | $27,600.75 | 12/24/2025 | Non-covered Recipient Entity Christopher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228749993 |
| Principal investigator 1 | PFIZER INC. | $64,719.00 | 12/17/2025 | Non-covered Recipient Entity Christpher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228722766 |
| Principal investigator 1 | PFIZER INC. | $59,008.50 | 12/17/2025 | Non-covered Recipient Entity Christopher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228730942 |
| Principal investigator 1 | PFIZER INC. | $143,407.25 | 12/16/2025 | Non-covered Recipient Entity Christpher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228733799 |
| Principal investigator 1 | PFIZER INC. | $86,953.50 | 12/16/2025 | Non-covered Recipient Entity Christopher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228746268 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $37,289.60 | 12/15/2025 | Non-covered Recipient Entity Certified Research Associates | A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent | No dispute reported | 06/30/2026 | 1232937518 |
| Principal investigator 1 | PFIZER INC. | $2,775.00 | 12/12/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228746870 |
| Principal investigator 1 | PFIZER INC. | $53,298.00 | 11/27/2025 | Non-covered Recipient Entity Christpher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228738365 |
| Principal investigator 1 | PFIZER INC. | $13,324.50 | 11/27/2025 | Non-covered Recipient Entity Christopher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228739177 |
| Principal investigator 1 | PFIZER INC. | $5,233.25 | 11/26/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228714489 |
| Principal investigator 1 | PFIZER INC. | $200.00 | 11/26/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228728345 |
| Principal investigator 1 | PFIZER INC. | $234.00 | 11/17/2025 | Non-covered Recipient Entity Finger Lakes Medical Research | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1228723632 |
| Principal investigator 1 | PFIZER INC. | $292.50 | 11/17/2025 | Non-covered Recipient Entity Finger Lakes Medical Research | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1228724784 |
| Principal investigator 1 | PFIZER INC. | $303.00 | 11/17/2025 | Non-covered Recipient Entity Finger Lakes Medical Research | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1228728641 |
| Principal investigator 1 | PFIZER INC. | $234.00 | 11/14/2025 | Non-covered Recipient Entity Finger Lakes Medical Research | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1228723036 |
| Principal investigator 1 | PFIZER INC. | $303.00 | 11/14/2025 | Non-covered Recipient Entity Finger Lakes Medical Research | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1228723740 |
| Principal investigator 1 | PFIZER INC. | $292.50 | 11/14/2025 | Non-covered Recipient Entity Finger Lakes Medical Research | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1228728339 |
| Principal investigator 1 | PFIZER INC. | $11.70 | 11/11/2025 | Non-covered Recipient Entity Finger Lakes Medical Research | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1228723630 |
| Principal investigator 1 | PFIZER INC. | $11.70 | 11/11/2025 | Non-covered Recipient Entity Finger Lakes Medical Research | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1228724780 |
| Principal investigator 1 | PFIZER INC. | $378.75 | 11/11/2025 | Non-covered Recipient Entity Finger Lakes Medical Research | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1228724782 |
| Principal investigator 1 | PFIZER INC. | $378.75 | 11/11/2025 | Non-covered Recipient Entity Finger Lakes Medical Research | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1228724858 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,836.85 | 11/07/2025 | Non-covered Recipient Entity FINGER LAKES MEDICAL RESEARCH | A PROSPECTIVE COHORT STUDY OF PATIENTS WITH REFRACTORY OR UNEXPLAINED | No dispute reported | 06/30/2026 | 1192130441 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,500.00 | 11/07/2025 | Non-covered Recipient Entity FINGER LAKES MEDICAL RESEARCH | A PROSPECTIVE COHORT STUDY OF PATIENTS WITH REFRACTORY OR UNEXPLAINED | No dispute reported | 06/30/2026 | 1192130449 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,500.00 | 11/07/2025 | Non-covered Recipient Entity FINGER LAKES MEDICAL RESEARCH | A PROSPECTIVE COHORT STUDY OF PATIENTS WITH REFRACTORY OR UNEXPLAINED | No dispute reported | 06/30/2026 | 1192133510 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $375.00 | 11/07/2025 | Non-covered Recipient Entity FINGER LAKES MEDICAL RESEARCH | A PROSPECTIVE COHORT STUDY OF PATIENTS WITH REFRACTORY OR UNEXPLAINED | No dispute reported | 06/30/2026 | 1192133518 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 11/05/2025 | Non-covered Recipient Entity Christopher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228729504 |
| Principal investigator 1 | PFIZER INC. | $2,360.00 | 11/01/2025 | Non-covered Recipient Entity Christpher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228729812 |
| Principal investigator 1 | PFIZER INC. | $2,594.55 | 11/01/2025 | Non-covered Recipient Entity Christopher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228739331 |
| Principal investigator 1 | PFIZER INC. | $10,469.80 | 10/31/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228741778 |
| Principal investigator 1 | PFIZER INC. | $19,895.20 | 10/25/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228740923 |
| Principal investigator 1 | PFIZER INC. | $7,535.88 | 10/25/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228741643 |
| Principal investigator 1 | PFIZER INC. | $3,385.80 | 10/09/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228741537 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,000.00 | 10/08/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192130435 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,901.00 | 10/08/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192130453 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $10,000.00 | 10/03/2025 | Non-covered Recipient Entity Finger Lakes Medical Research, Pllc | A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 4-arm Study to Investigate the Mixed Vaccination Schedules of a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers | No dispute reported | 06/30/2026 | 1226101011 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $50.00 | 10/03/2025 | Non-covered Recipient Entity Finger Lakes Medical Research, Pllc | A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 4-arm Study to Investigate the Mixed Vaccination Schedules of a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers | No dispute reported | 06/30/2026 | 1226101018 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 10/03/2025 | Non-covered Recipient Entity Finger Lakes Medical Research, Pllc | A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 4-arm Study to Investigate the Mixed Vaccination Schedules of a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers | No dispute reported | 06/30/2026 | 1226101024 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $410.00 | 10/03/2025 | Non-covered Recipient Entity Finger Lakes Medical Research, Pllc | A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 4-arm Study to Investigate the Mixed Vaccination Schedules of a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers | No dispute reported | 06/30/2026 | 1226101030 |
| Principal investigator 1 | PFIZER INC. | $1,228.00 | 09/24/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228762044 |
| Principal investigator 1 | PFIZER INC. | $1,500.00 | 08/21/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228766259 |
| Principal investigator 1 | PFIZER INC. | $222.75 | 08/20/2025 | Non-covered Recipient Entity Christopher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228767694 |
| Principal investigator 1 | PFIZER INC. | $1,376.27 | 08/14/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228723888 |
| Principal investigator 1 | PFIZER INC. | $1,169.27 | 08/14/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228724130 |
| Principal investigator 1 | PFIZER INC. | $10,242.45 | 08/06/2025 | Non-covered Recipient Entity Christopher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228784985 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $500.00 | 08/06/2025 | Non-covered Recipient Entity SMITH ALLERGY AND ASTHMA OF CENTRAL NEW YORK PLLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244044766 |
| Principal investigator 1 | PFIZER INC. | $131.75 | 08/04/2025 | Non-covered Recipient Entity Smith Allergy Asthma Spec | A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228714305 |
| Principal investigator 1 | PFIZER INC. | $199.32 | 08/04/2025 | Non-covered Recipient Entity Smith Allergy Asthma Spec | A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228714375 |
| Principal investigator 1 | PFIZER INC. | $757.50 | 08/04/2025 | Non-covered Recipient Entity Smith Allergy Asthma Spec | A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228714491 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $136.40 | 07/30/2025 | Non-covered Recipient Entity SMITH ALLERGY AND ASTHMA OF CENTRAL NEW YORK PLLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244044802 |
| Principal investigator 1 | PFIZER INC. | $5,676.12 | 07/25/2025 | Non-covered Recipient Entity Christopher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228782383 |
| Principal investigator 1 | PFIZER INC. | $438.75 | 07/23/2025 | Non-covered Recipient Entity Christopher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228773661 |
| Principal investigator 1 | PFIZER INC. | $3,412.80 | 07/16/2025 | Non-covered Recipient Entity Smith Allergy Asthma Specialists | A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228714377 |
| Principal investigator 1 | PFIZER INC. | $300.00 | 07/16/2025 | Non-covered Recipient Entity Christpher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228765153 |
| Principal investigator 1 | PFIZER INC. | $1,201.50 | 07/16/2025 | Non-covered Recipient Entity Christopher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228783872 |
| Principal investigator 1 | PFIZER INC. | $38,967.88 | 07/11/2025 | Non-covered Recipient Entity Christopher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228762973 |
| Principal investigator 1 | PFIZER INC. | $33,277.30 | 07/11/2025 | Non-covered Recipient Entity Christpher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228784089 |
| Principal investigator 1 | PFIZER INC. | $129.87 | 07/08/2025 | Non-covered Recipient Entity Corning Ctr for Clin Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228714301 |
| Principal investigator 1 | PFIZER INC. | $110.79 | 07/08/2025 | Non-covered Recipient Entity Corning Ctr for Clin Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228714303 |
| Principal investigator 1 | PFIZER INC. | $832.98 | 06/27/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228785561 |
| Principal investigator 1 | PFIZER INC. | $199,225.09 | 06/21/2025 | Non-covered Recipient Entity Christpher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228776145 |
| Principal investigator 1 | PFIZER INC. | $159,982.60 | 06/21/2025 | Non-covered Recipient Entity Christopher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228790847 |
| Principal investigator 1 | PFIZER INC. | $2,910.64 | 06/14/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228777144 |
| Principal investigator 1 | PFIZER INC. | $8,233.16 | 06/14/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228791629 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $500.00 | 06/13/2025 | Non-covered Recipient Entity SMITH ALLERGY AND ASTHMA OF CENTRAL NEW YORK PLLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244044764 |
| Principal investigator 1 | PFIZER INC. | $172,341.00 | 06/06/2025 | Non-covered Recipient Entity Christopher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228775253 |
| Principal investigator 1 | PFIZER INC. | $278,830.34 | 06/06/2025 | Non-covered Recipient Entity Christpher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228790642 |
| Principal investigator 1 | PFIZER INC. | $10,232.90 | 05/28/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228771960 |
| Principal investigator 1 | PFIZER INC. | $8,326.50 | 05/28/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228772458 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $93,111.47 | 05/13/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD | No dispute reported | 06/30/2026 | 1185547275 |
| Principal investigator 1 | PFIZER INC. | $2,191.88 | 05/07/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228781578 |
| Principal investigator 1 | PFIZER INC. | $555.32 | 05/06/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228763474 |
| Principal investigator 1 | PFIZER INC. | $555.32 | 05/06/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228783375 |
| Principal investigator 1 | PFIZER INC. | $1,643.91 | 05/02/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228764707 |
| Principal investigator 1 | PFIZER INC. | $3,311.83 | 05/01/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228764997 |
| Principal investigator 1 | PFIZER INC. | $4,089.26 | 05/01/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228778179 |
| Principal investigator 1 | PFIZER INC. | $309,081.39 | 04/30/2025 | Non-covered Recipient Entity Christpher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228795335 |
| Principal investigator 1 | PFIZER INC. | $230,475.69 | 04/29/2025 | Non-covered Recipient Entity Christopher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228720301 |
| Principal investigator 1 | PFIZER INC. | $661.50 | 04/26/2025 | Non-covered Recipient Entity Christopher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228798197 |
| Principal investigator 1 | PFIZER INC. | $72,990.85 | 04/10/2025 | Non-covered Recipient Entity Christopher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228778720 |
| Principal investigator 1 | PFIZER INC. | $72,640.05 | 04/10/2025 | Non-covered Recipient Entity Christpher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228781387 |
| Principal investigator 1 | PFIZER INC. | $1,731.64 | 04/08/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228723026 |
| Principal investigator 1 | PFIZER INC. | $626.90 | 04/08/2025 | Non-covered Recipient Entity Corning Center for Clinical | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228770968 |
| Principal investigator 1 | PFIZER INC. | $3,261.26 | 04/08/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228779473 |
| Principal investigator 1 | PFIZER INC. | $4,866.10 | 04/01/2025 | Non-covered Recipient Entity Christopher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228779811 |
| Principal investigator 1 | PFIZER INC. | $9,572.20 | 04/01/2025 | Non-covered Recipient Entity Christpher A Smith MD | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228794588 |
| Principal investigator 1 | PFIZER INC. | $10,893.91 | 03/22/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228766369 |
| Principal investigator 1 | PFIZER INC. | $20,188.78 | 03/22/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228796329 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $204.60 | 02/24/2025 | Non-covered Recipient Entity SMITH ALLERGY AND ASTHMA OF CENTRAL NEW YORK PLLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244044800 |
| Principal investigator 1 | PFIZER INC. | $16,052.30 | 02/22/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228752664 |
| Principal investigator 1 | PFIZER INC. | $23,661.44 | 02/22/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228757974 |
| Principal investigator 1 | PFIZER INC. | $101.25 | 02/19/2025 | Non-covered Recipient Entity Smith Allergy Athsma of Central New York PLLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228749731 |
| Principal investigator 1 | AstraZeneca UK Limited | $52,575.90 | 02/13/2025 | Non-covered Recipient Entity FINGER LAKES MEDICAL RESEARCH PLLC | a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA | No dispute reported | 06/30/2026 | 1185547273 |
| Principal investigator 1 | PFIZER INC. | $1,500.00 | 02/12/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228770278 |
| Principal investigator 1 | PFIZER INC. | $1,948.51 | 02/05/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228750190 |
| Principal investigator 1 | PFIZER INC. | $16,923.28 | 01/30/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228798267 |
| Principal investigator 1 | PFIZER INC. | $34,780.49 | 01/30/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228800799 |
| Principal investigator 1 | PFIZER INC. | $300.00 | 01/29/2025 | Non-covered Recipient Entity Smith Allergy Asthma of Central New YorkPLLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228801538 |
| Principal investigator 1 | PFIZER INC. | $661.50 | 01/15/2025 | Non-covered Recipient Entity Smith Allergy Athsma of Central New York PLLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228801937 |
| Principal investigator 1 | PFIZER INC. | $5,367.65 | 01/09/2025 | Non-covered Recipient Entity Smith Allergy Athsma of Central New York PLLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228799643 |